Showing results (61-70 of 67) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
International Journal of Antimicrobial Agents|September 18, 2024
The efficacy of keverprazan-based quadruple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind, multicentre trialNiandi Tan, Hao Wu, Cheng Lan, et al.The Lancet. Infectious Diseases|September 13, 2025
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trialZhiqiang Song, Liya Zhou, Weihong Wang, et al.Eclinicalmedicine|September 16, 2024
Efficacy of a real-time intelligent quality-control system for the detection of early upper gastrointestinal neoplasms: a multicentre, single-blinded, randomised controlled trialRuchen Zhou, Jing Liu, Chenchen Zhang, et al.Clinical and Translational Gastroenterology|January 21, 2025
A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (X842) and Lansoprazole for the Treatment of Patients With Erosive EsophagitisSiying Zhu, Muzhou Han, Ye Zong, et al.Gut|March 31, 2019
Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre studyQuancai Cai, Chunping Zhu, Yuan Yuan, et al.Journal of Gastroenterology and Hepatology|January 22, 2024
The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter studyQianjun Zhuang, Aijun Liao, Qingling He, et al.Chinese Medical Journal|August 22, 2025
Tegoprazan-based versus esomeprazole-based triple therapy plus bismuth for first-line Helicobacter pylori eradication: A nationwide, multicenter, double-blind, double-dummy, randomized controlled trialZhiqiang Song, Weihong Wang, Peng Li, et al.Pageof 7